Details of the Drug

General Information of Drug (ID: DMIZPF4)

Drug Name

KITE-363

Indication

Disease Entry	ICD 11	Status	REF
B-cell lymphoma	2A86	Phase 1	[1]
Diffuse large B-cell lymphoma	2A81	Phase 1	[1]
------------------------------------------------------------------------------------

Drug Type

CAR-T cell therapy

Cross-matching ID

Repurposed Drugs (RPD)

Molecular Interaction Atlas of This Drug

Drug Therapeutic Target (DTT)

DTT Name	DTT ID	UniProt ID	MOA	REF
B-lymphocyte surface antigen B4 (CD19)	TTW640A	CD19_HUMAN	Not Available	[2]
Leukocyte surface antigen Leu-16 (CD20)	TTUE541	CD20_HUMAN	Not Available	[2]

------------------------------------------------------------------------------------

Molecular Interaction Atlas (MIA)

Jump to Detail Molecular Interaction Atlas of This Drug

References

1	ClinicalTrials.gov (NCT04989803) A Phase 1 Open-label, Multicenter Study Evaluating the Safety and Efficacy of KITE-363 or KITE-753, Autologous Anti-CD19/CD20 CAR T-cell Therapies, in Subjects With Relapsed and/or Refractory B-cell Lymphoma. U.S.National Institutes of Health.
2	Clinical pipeline report, company report or official report of Gilead